Pancreatic Carcinoma Clinical Trial
Official title:
A Prospective Randomized Controlled Trial Evaluating an Accelerated 5 Day Pathway for Discharge Following Pancreaticoduodenectomy (PD): Whipple Accelerated Recovery Pathway (WARP Trial)
This randomized clinical trial studies accelerated recovery pathway for discharge after surgery in patients with pancreatic cancer. A standardized accelerated recovery pathway may improve outcomes after surgery following complex abdominal operations resulting in a shorter length of stay in patients with pancreatic cancer. It may also help patients to mobilize more quickly and return to the home setting, decrease hospital-acquired infectious complications, and increase potential cost savings. It is not yet known whether an accelerated recovery pathway is better than a standard recovery pathway for discharge following surgery in patients with pancreatic cancer.
PRIMARY OBJECTIVES:
I. The use of an accelerated pathway will result in a shorter postoperative hospital length
of stay for patients undergoing pancreaticoduodenectomy (PD) without an increase in
perioperative complications or readmission rates.
SECONDARY OBJECTIVES:
I. The investigators anticipate lower cost, lower readmission rate, similar rate of
post-operative complications (delayed gastric emptying [DGE], anastomotic leaks,
intra-abdominal abscesses, wound infection, urinary tract infection [UTI], respiratory
compromise, renal failure, etc.) in our study group.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients follow the standard 7-day pathway at the end of surgery.
ARM II: Patients follow the Whipple accelerated 5-day pathway at the end of surgery. The
accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and
enhanced physical therapy, multimodal pain control, dietary modifications, and increased and
standardized phone contact by a nurse practitioner during the first week following hospital
discharge.
After completion of study treatment, patients are followed up periodically.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT05237193 -
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
|
||
| Active, not recruiting |
NCT04602026 -
The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer
|
N/A | |
| Recruiting |
NCT05613465 -
Adjuvant Chemotherapy Plus Codonopsis Pilosula Nnannf /Placebo
|
N/A | |
| Completed |
NCT03645148 -
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT02587689 -
Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02676349 -
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
|
Phase 2 | |
| Active, not recruiting |
NCT03267524 -
Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers
|
N/A | |
| Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03164486 -
First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide
|
Early Phase 1 | |
| Active, not recruiting |
NCT02009449 -
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03137706 -
Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer
|
||
| Not yet recruiting |
NCT06080854 -
AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT03962478 -
Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction
|
N/A | |
| Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00907166 -
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06271291 -
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
|
||
| Active, not recruiting |
NCT03752398 -
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
|
Phase 1 | |
| Completed |
NCT03949933 -
Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer
|
N/A |